Sledovat
Michel CLANET
Michel CLANET
UT3 Professor, CHU Toulouse, CPTP (INSERM-UT3), TMBI (Univ.Toulouse)
E-mailová adresa ověřena na: inserm.fr
Název
Citace
Citace
Rok
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
CH Polman, SC Reingold, B Banwell, M Clanet, JA Cohen, M Filippi, ...
Annals of neurology 69 (2), 292-302, 2011
109492011
Defining the clinical course of multiple sclerosis: the 2013 revisions
FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ...
Neurology 83 (3), 278-286, 2014
37692014
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick, WH Stuart, PA Calabresi, C Confavreux, SL Galetta, ...
New England Journal of Medicine 354 (9), 911-923, 2006
17132006
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
X Montalban, R Gold, AJ Thompson, S Otero-Romero, MP Amato, ...
Multiple Sclerosis Journal 24 (2), 96-120, 2018
9302018
Natural history of multiple sclerosis with childhood onset
C Renoux, S Vukusic, Y Mikaeloff, G Edan, M Clanet, B Dubois, ...
New England Journal of Medicine 356 (25), 2603-2613, 2007
7222007
EFNS guidelines on diagnosis and management of neuromyelitis optica
J Sellner, M Boggild, M Clanet, RQ Hintzen, Z Illes, X Montalban, ...
European journal of neurology 17 (8), 1019-1032, 2010
6042010
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled …
L Kappos, G Comi, H Panitch, J Oger, J Antel, P Conlon, L Steinman, ...
Nature medicine 6 (10), 1176-1182, 2000
6022000
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
G Edan, D Miller, M Clanet, C Confavreux, O Lyon-Caen, C Lubetzki, ...
Journal of Neurology, Neurosurgery & Psychiatry 62 (2), 112-118, 1997
5871997
Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations
F Bergametti, C Denier, P Labauge, M Arnoult, S Boetto, M Clanet, ...
The American Journal of Human Genetics 76 (1), 42-51, 2005
5062005
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study
B Stankoff, E Waubant, C Confavreux, G Edan, M Debouverie, ...
Neurology 64 (7), 1139-1143, 2005
387*2005
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
L Kappos, D Bates, G Edan, M Eraksoy, A Garcia-Merino, N Grigoriadis, ...
The Lancet Neurology 10 (8), 745-758, 2011
3742011
A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis
C Desnuelle, M Dib, C Garrel, A Favier
Amyotrophic Lateral Sclerosis and other motor neuron disorders 2 (1), 9-18, 2001
3512001
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study
A Tourbah, C Lebrun-Frenay, G Edan, M Clanet, C Papeix, S Vukusic, ...
Multiple Sclerosis Journal 22 (13), 1719-1731, 2016
3452016
Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification
G Nicolas, C Pottier, D Maltête, S Coutant, A Rovelet-Lecrux, S Legallic, ...
Neurology 80 (2), 181-187, 2013
2942013
A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS
M Clanet, EW Radue, L Kappos, HP Hartung, R Hohlfeld, ...
Neurology 59 (10), 1507-1517, 2002
2822002
Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings
AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ...
Neurology 89 (11), 1117-1126, 2017
2772017
Neutralizing antibodies and efficacy of interferon β-1a: a 4-year controlled study
L Kappos, M Clanet, M Sandberg-Wollheim, EW Radue, HP Hartung, ...
Neurology 65 (1), 40-47, 2005
2602005
Neuromyelitis optica in France: a multicenter study of 125 patients
N Collongues, R Marignier, H Zephir, C Papeix, F Blanc, C Ritleng, ...
Neurology 74 (9), 736-742, 2010
2582010
Abnormal ocular movements in Parkinson's disease: evidence for involvement of dopaminergic systems
O Rascol, M Clanet, JL Montastruc, M Simonetta, MJ Soulier-Esteve, ...
Brain 112 (5), 1193-1214, 1989
2551989
Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy
E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ...
Neurology 89 (11), 1107-1116, 2017
2312017
Systém momentálně nemůže danou operaci provést. Zkuste to znovu později.
Články 1–20